Business Description
89bio Inc
NAICS : 325412
SIC : 2834
ISIN : US2825591033
Share Class Description:
ETNB: Ordinary SharesCompare
Compare
Traded in other countries / regions
ETNB.USA Index Membership
Russell 2000Russell 3000Russell 2000 IPO Date
2019-11-11Description
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 17 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | -0.1 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 8.2 | |||||
| 3-Year EPS without NRI Growth Rate | 7.8 | |||||
| 3-Year FCF Growth Rate | 2.8 | |||||
| 3-Year Book Growth Rate | -18.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 13.45 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.36 | |||||
| 9-Day RSI | 46.22 | |||||
| 14-Day RSI | 51.72 | |||||
| 3-1 Month Momentum % | 44.81 | |||||
| 6-1 Month Momentum % | 25.83 | |||||
| 12-1 Month Momentum % | 26.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 18.03 | |||||
| Quick Ratio | 18.03 | |||||
| Cash Ratio | 16.86 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -80.7 | |||||
| Shareholder Yield % | -27.89 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -80.23 | |||||
| ROA % | -69.51 | |||||
| ROIC % | -3544.27 | |||||
| 3-Year ROIIC % | -7228.43 | |||||
| ROC (Joel Greenblatt) % | -11109.24 | |||||
| ROCE % | -73.45 | |||||
| Moat score | 3 | |||||
| Tariff score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.43 | |||||
| Price-to-Tangible-Book | 2.43 | |||||
| EV-to-EBIT | -2.16 | |||||
| EV-to-Forward-EBIT | -2.34 | |||||
| EV-to-EBITDA | -2.16 | |||||
| EV-to-Forward-EBITDA | -2.39 | |||||
| EV-to-FCF | -2.05 | |||||
| Price-to-Net-Current-Asset-Value | 2.45 | |||||
| Price-to-Net-Cash | 2.64 | |||||
| Earnings Yield (Greenblatt) % | -46.3 | |||||
| FCF Yield % | -27.12 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers